Evidence map›Paper›PMID 36110958›Full record

ArticleFrontiers in oncology2022

Publication trends and hotspots of drug resistance in colorectal cancer during 2002-2021: A bibliometric and visualized analysis.

Peng-Yue Zhao, Ya-Nan Jiao, Zhao-Fu Ma, Yang Yan, Yu-Xuan Li, Shi-Dong Hu, Song-Yan Li, Xiao-Hui Du

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peng-Yue ZhaoDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Ya-Nan JiaoDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Zhao-Fu MaDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Yang YanDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Yu-Xuan LiDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Shi-Dong HuDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Song-Yan LiDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Xiao-Hui DuDepartment of General Surgery, First Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China.
Chinese People's Liberation Army · CNChinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chemotherapy, radiotherapy, targeted therapy and immunotherapy have demonstrated expected clinical efficacy, while drug resistance remains the predominant limiting factor to therapeutic failure in patients with colorectal cancer (CRC). Although there have been numerous basic and clinical studies on CRC resistance in recent years, few publications utilized the bibliometric method to evaluate this field. The objective of current study was to provide a comprehensive analysis of the current state and changing trends of drug resistance in CRC over the past 20 years. Methods: The Web of Science Core Collection (WOSCC) was utilized to extracted all studies regarding drug resistance in CRC during 2002-2021. CiteSpace and online platform of bibliometrics were used to evaluate the contributions of various countries/regions, institutions, authors and journals in this field. Moreover, the recent research hotspots and promising future trends were identified through keywords analysis by CiteSpace and VOSviewer. Results: 1451 related publications from 2002 to 2021 in total were identified and collected. The number of global publications in this field has increased annually. China and the USA occupied the top two places with respect to the number of publications, contributing more than 60% of global publications. Sun Yat-sen University and Conclusions: The number of publications and research interest on drug resistance in CRC have been increasing annually. The USA and China were the main driver and professor Bardelli A was the most outstanding researcher in this field. Previous studies have mainly concentrated on growth factor receptor and induced apoptosis. Oxaliplatin resistance, microRNA and EMT as recently appeared frontiers of research that should be closely tracked in the future.

Indexed as

bibliometric analysiscolorectal cancerdrug resistanceEMTmicroRNA

Identifiers

PMID36110958
PMCPMC9469653
OpenAlexW4293696649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.